evexias bpc-157 lpt Glutathione BPC LPT by Evexias –

BPC-157 single-compound vial for protocols that require BPC-157 alone or at a non-1:1 ratio to TB-500

It had been placed in a restricted compounding category and was removed from that restricted list in April 2026 as part of a procedural review reset but removal is not approval

Research indicates it supports healthy inflammatory tone, neuro-immune homeostasis, and GI comfort, partly via PPAR- and endocannabinoid signaling pathways

Thus, fibroblast therapy may offer a potential therapeutic option for the treatment of IDD

Lidocaine infusions were initially started to manage neuropathic pain

This helps prevent localized skin irritation, bruising, and the buildup of scar tissue at any single location